MAIA Biotechnology, Inc. (MAIA)
| Market Cap | 73.15M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -23.72M |
| Shares Out | 21.84M |
| EPS (ttm) | -1.58 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 152,774 |
| Open | 3.460 |
| Previous Close | 3.440 |
| Day's Range | 3.300 - 3.600 |
| 52-Week Range | 0.820 - 5.990 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 6, 2024 |
About MAIA
MAIA Biotechnology, Inc., a targeted therapy, immuno-oncology company, focuses on the development and commercialization of drugs with novel mechanisms of action that are intended to improve and extend the lives of people with cancer. Its lead program is THIO, a potential cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. The company was incorporated in 2018 and is headquartered in Chicago, Illinois. [Read more]
Financial Performance
Financial StatementsNews
MAIA Biotechnology's Telomere Targeting Functionality is Shown Viable by FDA's Approval of a Telomerase Inhibitor Agent Therapy
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology's Telomere Targeting Functionality is Shown Viable by FDA's Approval of a Telomerase Inhibitor Agent Therapy.
MAIA Biotechnology Announces Year-to-Date Achievements and Highlights Recent Clinical Progress for Novel Anticancer Agent
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Year-to-Date Achievements and Highlights Recent Clinical Progress for Novel Anticancer Agent.
MAIA Biotechnology Reveals New Clinical Data Showing THIO's Strong Efficacy in Non-Small Cell Lung Cancer
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Reveals New Clinical Data Showing THIO's Strong Efficacy in Non-Small Cell Lung Cancer.
MAIA Biotechnology to Present at the BIO International Convention 2024
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology to Present at the BIO International Convention 2024.
MAIA Biotechnology Abstract Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Abstract Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting.
MAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private Placement
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private Placement.
MAIA Biotechnology Announces Share Purchase by Director Stan Smith, Ph.D. in Private Placement
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Share Purchase by Director Stan Smith, Ph.D. in Private Placement.
MAIA Biotechnology Announces $1.00 Million Private Placement
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces $1.00 Million Private Placement.
MAIA Biotechnology to Present at Two Investor Conferences in April 2024
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology to Present at Two Investor Conferences in April 2024.
MAIA Biotechnology Announces Share Purchases by Directors Cristian Luput and Ramiro Guerrero
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Share Purchases by Directors Cristian Luput and Ramiro Guerrero.
MAIA Biotechnology Announces $1.33 Million Private Placement
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces $1.33 Million Private Placement.
MAIA Biotechnology Announces Share Purchase by Director Stan Smith, PhD in a $2.9 Million Private Placement
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Share Purchase by Director Stan Smith, PhD in a $2.9 Million Private Placement.
MAIA Biotechnology Welcomes Prominent Medical Oncology Scientist Dr. Saadettin Kilickap to its Scientific Advisory Board
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Welcomes Prominent Medical Oncology Scientist Dr. Saadettin Kilickap to its Scientific Advisory Board.
MAIA Biotechnology to Participate in the 36th Annual ROTH Conference
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology to Participate in the 36th Annual ROTH Conference.
MAIA Biotechnology and Nationwide Children's Hospital Announce Presentation of THIO's Potency in Pediatric Brain Tumors at American Association of Cancer Research Annual Meeting
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology and Nationwide Children's Hospital Announce Presentation of THIO's Potency in Pediatric Brain Tumors at AACR Annual Meeting.
MAIA Biotechnology Announces Strong Efficacy of THIO as Third-Line Treatment for Non-Small Cell Lung Cancer Patients
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Strong Efficacy of THIO as Third-Line Treatment for Non-Small Cell Lung Cancer Patients.
MAIA Biotechnology CEO Details Immuno-Oncology Cancer Treatment Candidates and Development Pipeline in Letter to Shareholders
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology CEO Details Immuno-Oncology Cancer Treatment Candidates and Development Pipeline in Letter to Shareholders.
MAIA Biotechnology Appoints Leading Immuno-Oncology Scientist Dr. Remus Vezan as Scientific Advisor
CHICAGO, IL, Feb. 27, 2024 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies f...
MAIA Biotechnology Completes Enrollment in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer
CHICAGO, IL, Feb. 22, 2024 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies f...
MAIA Biotechnology Announces Publication in Nature Communications on Positive Effects of THIO for Potential Treatment of Small Cell Lung Cancer
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Publication in Nature Communications on Positive Effects of THIO for Potential Treatment of Small Cell Lung Cancer.
MAIA Biotechnology Announces Publication of International PCT Patent Application Covering Anticancer Telomere-Targeting Compounds
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Publication of International PCT Patent Application Covering Anticancer Telomere-Targeting Compounds.
MAIA Biotechnology Provides Positive Phase 2 Clinical Updates for Lead Anticancer Agent and Outlines Targeted Milestones for 2024
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Provides Positive Phase 2 Clinical Updates for Lead Anticancer Agent and Outlines Targeted Milestones for 2024.
MAIA Biotechnology to Present at Biotech Showcase 2024 on January 9, 2024
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology to Present at Biotech Showcase 2024 on January 9, 2024.
MAIA Biotechnology Announces Dose Selection in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Dose Selection in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer.
MAIA Biotechnology Announces Closing of $4 Million Registered Direct Offering
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Closing of $4 Million Registered Direct Offering.